Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer Novel combination therapy will be studied as part of the Phase II adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute Study builds on the previously reported positive Phase II res

MONMOUTH JUNCTION, N.J., March 4, 2026 /PRNewswire/ -- TheWell Bioscience, a leader in advanced xeno-free cell culture technologies, today announced the launch of RocketCell™ hMSC Xeno-Free Complete Growth Medium, a chemically defined, xeno-free medium engineered for high-performance human mesenchymal stem cell (hMSC) expansion and exosome production across research, translational development, and cell therapy manufacturing workflows. Continue Reading RocketCell™ hMSC Xeno-Free Complete Growth

LONDON, March 4, 2026 /PRNewswire/ -- iLoF, the leading company pioneering Optomics®, the AI-powered photonics platform for developing personalised solutions for drug development and clinical research, announces today a strategic collaboration with Bluepharma, a global pharmaceutical company specializing in the research, development, and manufacturing of innovative healthcare products. The partnership will integrate Optomics® across the pharmaceutical value chain and enable the parties to explor

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT rem

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL UBS Biotech Summit Date: March 9, 2026 Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Date: March 10, 2026 Location: Miami, FL About Harmony Biosciences Harmony Biosciences is a pharmaceutical com

A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage s

New public opinion data from 2,569 respondents reveals near-unanimous opposition to key provisions of the administration’s glyphosate executive orderAUSTIN, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- The Informed Consent Action Network (ICAN) released the results of a public opinion poll conducted in response to the Trump Administration’s executive order directing federal agencies to stockpile glyphosate-based herbicides. The poll, which drew 2,569 respondents, found sweeping opposition to fede

U.S. government fortifies commitment to advanced manufacturing technology for the domestic production of essential medicines MENLO PARK, Calif., March 4, 2026 /PRNewswire/ -- Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million. The additional fun

WASHINGTON--(BUSINESS WIRE)--Today, the Pharmaceutical Reform Alliance (PRA) released a report explaining how the pharmaceutical industry’s anti-competitive and anti-consumer business practices have led to higher healthcare costs, contributing to America’s affordability crisis. PRA is publishing the report, entitled "The State of U.S. Drug Pricing: Unaffordable," as healthcare affordability remains a top concern for American families, especially heading into this year’s elections. The report exp

Compassionate Use Case Reports Continued Symptom Improvement and Imaging-Confirmed Device Patency Through Three-Year Follow-Up BOSTON, March 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel minimally invasive treatments for neurological diseases, today announced the publication of a first-in-human case report describing the use of the eShunt System to treat medically refractory idiopathic intracranial hypertension (IIH), formerly known as pseudotum